These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34563605)

  • 1. Programmed necroptosis is upregulated in low-grade myelodysplastic syndromes and may play a role in the pathogenesis.
    Zou J; Shi Q; Chen H; Juskevicius R; Zinkel SS
    Exp Hematol; 2021 Nov; 103():60-72.e5. PubMed ID: 34563605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice.
    Wagner PN; Shi Q; Salisbury-Ruf CT; Zou J; Savona MR; Fedoriw Y; Zinkel SS
    Blood; 2019 Jan; 133(2):107-120. PubMed ID: 30413413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.
    Montalban-Bravo G; Class CA; Ganan-Gomez I; Kanagal-Shamanna R; Sasaki K; Richard-Carpentier G; Naqvi K; Wei Y; Yang H; Soltysiak KA; Chien K; Bueso-Ramos C; Do KA; Kantarjian H; Garcia-Manero G
    Leukemia; 2020 Mar; 34(3):872-881. PubMed ID: 31719677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice.
    Liu S; Joshi K; Zhang L; Li W; Mack R; Runde A; Hagen PA; Barton K; Breslin P; Ji HL; Kini AR; Wang Z; Zhang J
    Cell Death Dis; 2024 Apr; 15(4):278. PubMed ID: 38637559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study.
    Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
    J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
    Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
    Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
    Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
    PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML.
    Li LJ; Tao JL; Fu R; Wang HQ; Jiang HJ; Yue LZ; Zhang W; Liu H; Shao ZH
    Int J Hematol; 2014 Jul; 100(1):60-9. PubMed ID: 24846193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Dostalova Merkerova M; Krejcik Z; Votavova H; Belickova M; Vasikova A; Cermak J
    Eur J Hum Genet; 2011 Mar; 19(3):313-9. PubMed ID: 21150891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
    Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
    Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.
    Pang WW; Pluvinage JV; Price EA; Sridhar K; Arber DA; Greenberg PL; Schrier SL; Park CY; Weissman IL
    Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3011-6. PubMed ID: 23388639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
    Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
    Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
    Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
    Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
    Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
    Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.